Inhibition of proliferation, VEGF secretion of human neuroendocrine tumor cell line NCI-H727 by an antagonist of growth hormone-releasing hormone (GH-RH) in vitro

Cancer Letters

Volumn 268, Issue 1, 2008, Pages 120-128

  Sacewicz, Małgorzata ^a   Ławnicka, Hanna ^a   Siejka, Agnieszka ^a   Stepień, Tomasz ^a   Krupiński, Roman ^a   Komorowski, Jan ^a   Stepień, Henryk ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Angiogenesis; GH RH analogues; Neuroendocrine tumors; Proliferation; VEGF

Indexed keywords

BROXURIDINE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR RECEPTOR; HORMONE ANTAGONIST; JV [1-36]; VASCULOTROPIN;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN NCI H727; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH HORMONE RELEASE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GROWTH HORMONE-RELEASING HORMONE; HUMANS; IMMUNOHISTOCHEMISTRY; NEUROENDOCRINE TUMORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 48149110987     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.03.041     Document Type: Article

References (38)

1. Kiaris H., Schally A.V., Varga J.L., Groot K., and Armatis P. Growth hormone-releasing hormone: an autocrine growth factor for small lung carcinoma. Proc. Natl. Acad. Sci. USA 96 (1999) 14894-14898
2. Chatzistamou I., Schally A.V., Varga J.L., Groot K., Armatis P., Busto R., and Halmos G. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice. J. Clin. Endocrinol. Metab. 86 (2001) 2144-2152
3. Busto R., Schally A.V., Varga J.L., Garcia-Fernandez M.O., Groot K., Armatis P., and Szepeshazi K. The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas. Proc. Natl. Acad. Sci. USA 99 (2002) 11866-11871
4. Havt A., Schally A.V., Halmos G., Varga J.L., Toller G.L., Horvath J.E., Szepeshazi K., Ko{combining double acute accent}ster F., Kovitz K., Groot K., Zarandi M., and Kanashiro M. The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc. Natl. Acad. Sci. USA 48 (2005) 17424-17429
5. Chatzistamou I., Schally A.V., Kiaris H., Politi E., Varga J., Kanelis G., Kalofoutis A., Pafiti A., and Koutselini H. Immunohistochemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers. Eur. J. Endocrinol. 151 (2004) 391-396
6. Robberecht P., Coy D.H., Waelbroeck M., Heiman M.L., de Neef P., Camus J.C., and Christophe J. Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): discovery of (N-Ac-Tyr1, d-Arg2)-GRF(1-29)-NH2 as a GRF antagonist on membranes. Endocrinology 117 (1985) 1759-1764
7. Varga J.L., Schally A.V., Csernus V.J., Zarandi M., Halmos G., Groot K., and Rekasi Z. Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc. Natl. Acad. Sci. USA 96 (1999) 692-697
8. Schally A.V., Varga J.L., and Engel J.B. Antagonists of growth hormone-releasing hormone: an emerging new therapy for cancer. Nat. Clin. Pract. Endocrinol. Metab. 4 (2008) 33-43
9. Chatzistamou I., Schally A.V., Varga JL J.L., Groot K., Brusto R., Armatis P., and Halmos G G. Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone. Anticancer Drugs 12 (2001) 761-768
10. Halmos G., Schally A.V., Varga J.L., Planowski A., Rekasi Z., and Czomploy T. Human renal cell carcinoma express distinct binding sites for growth hormone - releasing hormone. Proc. Natl. Acad. Sci. USA 97 (2000) 10555-10560
11. Hohla F., Schally A.V., Szepeshazi K., Varga J.L., Buchholz S., Koster F., Heinrich E., Halmos G., Rick F.G., Kannadka C., Datz C., and Kanashiro C.A. Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel. Proc. Natl. Acad. Sci. USA 103 (2006) 14513-14518
12. Csernus V.J., Schally A.V., Kiaris H., and Armatis P. Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proc. Natl. Acad. Sci. USA 96 (1999) 3098-3103
13. Siejka A., Ławnicka H., Komorowski J., Schally A.V., Ste{ogonek}pień T., Krupiński R., and Ste{ogonek}pień H. GH-RH antagonist (MZ-4-71) inhibits VEGF secretion and proliferation of murine endothelial cells. Life Sci. 72 (2003) 2473-2479
14. Plonowski A., Schally A.V., Krupa A., Hebert F., Groot K., and Varga J.L. The inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone is not correlated with the suppression of serum IGF-I or tumoral IGF-II and vascular endothelial growth factor. Prostate 52 (2002) 173-182
15. Letsch M., Schally A.V., Busto R., Bajo A.M., and Varga J.L. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proc. Natl. Acad. Sci. USA 100 (2003) 1250-1255
16. Kanashiro C.A., Schally A.V., Zarandi M., Hammann B.D., and Varga J.L. Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer. Int. J. Oncol. 30 (2007) 1019-1028
17. Comaru-Schally A.M., and Schally A.V. A clinical overview of carcinoid tumors: perspectives for improvement in treatment using peptide analogs. Int. J. Oncol. 26 (2005) 301-309 (Review)
18. Kulke M.H., and Mayer R.J. Carcinoid tumors. N. Engl. J. Med. 340 (1999) 858-868
19. Hage R., Brutel de la Rivière A., Seldenrijk C.A., and van den Bosch J.M.M. Update in pulmonary carcinoid tumors: a review article. Ann. Surg. Oncol. 10 (2003) 697-704
20. Schally A.V., and Nagy A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci. 72 (2003) 2305-2320
21. Jungwirth A., Schally A.V., Pinski J., Groot K., and Halmos G. Growth hormone-releasing hormone (GH-RH) antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. Proc. Natl. Acad. Sci. USA 94 (1997) 5810-5813
22. Braczkowski R., Schally A.V., Plonowski A., Varga J.L., Groot K., Krupa M., and Armatis P. Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II. Cancer 95 (2002) 1735-1745
23. Kineman R.D. Antitumorigenic actions of growth hormone-releasing hormone antagonists. Proc. Natl. Acad. Sci. USA 97 (2000) 532-534
24. Lamharzi N., Schally A.V., Koppan M., and Groot K. Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors. Proc. Natl. Acad. Sci. USA 95 (1998) 8864-8868
25. Szepeshazi K., Schally A.V., Groot K., Armatis P., Halmos G., Herbert F., Szende B., Varga J.V., and Zarandi M. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Br. J. Cancer 82 (2000) 1724-1731
26. Chopin L.K., and Herington A.C. A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines. Prostate 49 (2001) 116-121
27. Garcia-Fernandez M.O., Schally A.V., Varga J.L., Groot K., and Busto R. The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanism in the stimulation of cell proliferation. Breast Cancer Res. Treat. 77 (2003) 15-26
28. Busto R., Schally A.V., Varga J.V., Garcia-Fernandez M.O., Groot K., Armatis P., and Szepeshazi K. The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas. Proc. Natl. Acad. Sci. USA 99 (2002) 11866-11871
29. Szereday Z., Schally A.V., Varga J.L., Kanashiro C.A., Hebart F., Armatis P., Groot K., Szepeshazi K., Halmos G., and Busto R. Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma. Cancer Res. 63 (2003) 7913-7919
30. Kiaris H., Chatzistamou I., Schally A.V., Halmos G., Varga J.V., Koutselini H., and Kalofutis A. Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor. Proc. Natl. Acad. Sci. USA 100 (2003) 9512-9517
31. Gaylinn B.D., Nass R., Toogood A.A., and Thorner M.O. Growth hormone-releasing hormone and growth hormone secretagous: basic physiology and clinical implications. fourth ed. In: DeGroot J.L., and Jameson J.L. (Eds) (2001), Saunders Company 405-426
32. Rekasi Z., Czomploy T., Schally A.V., and Gabor H. Isolation and sequencing of cDNA for splice variants of growth hormone-releasing hormone receptors for human cancers. Proc. Natl. Acad. Sci. USA 97 (2000) 10561-10566
33. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
34. Hanahan D., and Folkman J. Patterns and emerging mechanisms of angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
35. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18 (1997) 4-25
36. Stepien H.M., Kolomecki K., Pasieka Z., Komorowski J., Stepien T., and Kuzdak K. Angiogenesis of endocrine gland tumors - new molecular targets in diagnostics and therapy. Eur. J. Endocrinol. 146 (2002) 143-151
37. Rak J.W., St Croix B.D., and Kerbel R.S. Consequences of angiogenesis for tumor progression, metastasis, and cancer therapy. Anticancer Drugs 6 (1995) 3-18
38. Stangelberger A., Schally A.V., Zarandi M., Heinrich E., Groot K., Havt A., Kanashiro C.A., Varga J.L., and Halmos G. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers. Prostate 67 (2007) 1339-1353